Nivolumab (Opdivo) demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer (NSCLC)
Immune Checkpoint Regulation: The role of the PD-1/PDL1 pathway.
October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell …